What Is 17-Hydroxyprogesterone capronate

Overview

17-Hydroxyprogesterone capronate (17-OHPC) is a synthetic progestogen hormone used in obstetric medicine to reduce the risk of preterm birth. It was developed as a long-acting injectable form of progesterone to support pregnancy in women with a history of spontaneous preterm delivery.

The drug functions by mimicking the actions of natural progesterone, which helps maintain uterine quiescence and cervical integrity during pregnancy. Despite initial FDA approval, ongoing debate surrounds its clinical effectiveness and continued use in medical practice.

• 17-OHPC was first synthesized in the 1950s as part of early research into synthetic progestins for reproductive health, laying the foundation for later clinical applications.
• The compound is a 17-alpha-hydroxyprogesterone derivative with a caproate ester side chain, which prolongs its half-life and allows weekly dosing.
• It was originally used off-label for decades before receiving formal FDA approval in May 2011 under the brand name Makena.
• The approval was based on a pivotal trial showing a 33% relative reduction in preterm births before 37 weeks in women with prior preterm delivery.
• Despite approval, the FDA required a post-marketing trial to confirm efficacy, which ultimately failed to demonstrate significant benefit, leading to regulatory reconsideration.

How It Works

17-Hydroxyprogesterone capronate functions by modulating hormonal pathways critical to maintaining pregnancy. It acts primarily as a progestogen, suppressing uterine contractions and supporting cervical structure to prevent premature labor.

• Mechanism of Action: 17-OHPC binds to intracellular progesterone receptors, altering gene expression to reduce inflammation and myometrial sensitivity, thereby delaying labor onset.
• Pharmacokinetics: After intramuscular injection, the capronate ester allows slow release, with peak serum levels reached in 4 to 5 days and a half-life of approximately 15 days.
• Dosing Regimen: The standard dose is 250 mg weekly via intramuscular injection, beginning between 16 and 20 weeks of gestation and continuing until 37 weeks or delivery.
• Metabolism: The drug is metabolized in the liver into inactive compounds, primarily excreted via the kidneys, with minimal placental transfer to the fetus.
• Target Population: It is indicated for women with a singleton pregnancy and a history of spontaneous preterm birth before 37 weeks, not for multiple gestations or other risk factors.
• Biological Pathway: 17-OHPC reduces production of inflammatory cytokines and matrix metalloproteinases, which are associated with cervical ripening and membrane rupture.

Key Comparison

This comparison highlights how 17-OHPC differs from other progesterone forms in formulation, delivery, and regulatory status. While initial data supported its use, subsequent studies failed to confirm benefit, unlike vaginal progesterone, which maintains stronger evidence in certain populations.

Key Facts

Understanding the clinical and regulatory history of 17-hydroxyprogesterone capronate is essential for evaluating its role in modern obstetrics. Below are key facts supported by clinical trials and regulatory actions.

• 2011 FDA approval was granted under accelerated pathways based on a trial showing reduced preterm birth, though long-term infant outcomes were not significantly improved.
• The confirmatory trial, PROLONG, published in 2019, found no statistically significant difference in preterm birth rates between 17-OHPC and placebo groups.
• In June 2020, the FDA requested removal of Makena from the market due to lack of proven efficacy, marking a rare post-approval withdrawal.
• Despite withdrawal, some compounding pharmacies continue to produce 17-OHPC, raising concerns about unregulated use and cost, with doses previously priced over $1,000 monthly.
• A 2023 Cochrane review concluded there is low-certainty evidence supporting 17-OHPC for preterm birth prevention, citing methodological flaws in existing studies.
• The drug has been associated with increased risk of fetal anomalies in animal studies, though human data remain inconclusive, warranting caution.

Why It Matters

The story of 17-OHPC underscores the complexities of drug approval, post-market surveillance, and the balance between hope and evidence in high-risk pregnancies. It highlights how regulatory decisions evolve with new data.

• Its initial approval gave hope to thousands of women with prior preterm birth, offering a potential 33% relative risk reduction in recurrence based on early trials.
• The withdrawal of Makena illustrates the FDA's commitment to evidence-based medicine, even when reversing prior decisions to protect public health.
• Ongoing use in compounded form raises ethical concerns about patient access versus unproven benefit, especially given high treatment costs.
• It emphasizes the need for rigorous confirmatory trials when drugs are approved under accelerated pathways, ensuring long-term safety and efficacy.
• The case has influenced regulatory policy, prompting calls for stricter oversight of compounded bioidentical hormones in reproductive medicine.

As research continues into better predictors and treatments for preterm birth, the legacy of 17-OHPC serves as a cautionary tale about balancing innovation with scientific rigor in maternal-fetal care.